Effect of Dexamethasone Administration toward Hematopoietic Stem Cells and Blood Progenitor Cells Expression on BALB/c Mice
Wira Eka Putra, Aris Soewondo, Muhaimin Rifa'i
J. Pure App. Chem. Res. Vol 4, No 3 (2015), pp. 100-108
Submitted: October 07, 2015     Accepted: January 13, 2016     Published: December 14, 2016
DOI: http://dx.doi.org/10.21776/ub.jpacr.2015.004.03.221

Abstract


Cover Image

Hematopoiesis play important roles on maintaining body homeostasis. Dexamethasone (Dex) known as synthetic glucocorticoids and widely affect many regulations i.e. immune system, inflammation, reproduction and all aspects of metabolism. Generally Dex were used as therapeutic agentsto ameliorate many kind of diseases including cancer and auto-immune diseases. The aims of this research were to investigate the effect of Dex administration toward expression of hematopoietic stem cells and blood progenitor cells. Two weeks old BALB/c mice were used and treated with 3 groups of Dex administration i.e. untreated-mice, 0.5 mg/kg BW, and 10 mg/kg BW. Mice were sacrificed on day-7 after administration of Dex. The bone marrow stromal cells were isolated, then followed by flow cytometry analysis. The result showed that, Dex administration with dose 0.5 mg/kg BW significantly increase the expression of hematopoietic stem cells, CD34+, chemokines, SDF-1+, erythroid progenitor cells, Gr-1-TER-119+, granulocytes, Gr-1+, and B progenitor cells, B220+.


Keywords : Medicinal Chemistry
Full Text: PDF


References


Smith C., Cancer Control, 2003, 10 (1), 9-16.

Warr MR., Pietras EM., and Passegue E., WIREs Syst Biol Med, 2011, DOI: 10.1002/wsbm.145.

Gruver-Yates AL., Quinn MA., and Cidlowski JA., Endocrinology, 2014, 155(2): 463– 474.

Bindreither D., Ecker S., Gschirr B., Kofler A., Kofler R., and Rainer J. BMC Genomics, 2014, 15, 662.

Paula CB., Tan J., Shytle RD., Sanberg CD., El- Badri N., and Sanberg PR. Stem Cells Dev., 2006, 15,118–123.

Grace U, Ogbonnia S, Ehianeta T, and Bashir S. 2013., Int. J. Pharm. Pharm. Sci., 2013, 59 (2).

Webster-Marketon, Jeanette, Burnsides, Corry, Alexander, Balint, Cosmar & Philips., J. Inflam. Res., 2012, 89.

Galon J., Franchimont D., Hiroi N., Frey G., Boettner A., Ehrhart-Bornstein M., O’Shea JJ., Chrousos GP., and Bornstein SR., FASEB J1, 2002, 6(1), 61-71.

INCHEM, Dexamethasone (WHO Food Additives Series 33). http://www.inchem.org/ documents/jecfa/jecmono/v33je09.htm, Accessed 04/05/2015.

Weissman IL., Cell, 2000,100, 157-168.

Lemischka I., Rev Clin Exp Hematol, 2001, 5,15-25.

Hoffbrand AV., Pettit JE., and Moss PAH., Hematologi, 2005, EGC Press, Jakarta.

Kim H., Ji-Young C., Jung ML., Yoon SP., Hwal S., Hae-Ryong S., Sangmee AJ., and Inho J., FEBS Letters, 2008, 582 (23-24), 3509–14.

Askari AT., Unzek S., Popovic ZB., Goldman CK., Forudi F., Kiedrowski M., Rovner A., Ellis SG., Thomas JD., Di Corleto PE., Topol EJ., and Penn MS, Lancet, 2003, 362(9385), 697–703.

Lapidot T. and Petit I., Exp. Hematol, 2002, 30(9), 973–981.

Lataillade, Jean-Jacques, Clay D., Dupuy C., Rigal S., Jasmin C., Bourin P., and Marie-Caroline Le Bousse-Kerdilès, Blood, 2000, 95(3), 756–68.

Gazitt Y. and Liu Q., Stem Cells, 2001, 19 (1), 37–45.

Kim SW., Ha-Yon K., Hyo-Jin L., Hwan-Jung Y., Samyong K., and Deog-Yeon J., Leukemia Lymphoma, 2009, 50 (7), 1163–73.

Abraham M., Beider K., Wald H., Weiss ID., Zipori D., Galun E., Nagler A., Eizenberg O., and Peled A., Leukemia, 2009, 23 (8),1378–88.

Kollet O., Vagima Y., D’Uva G., Golan K., Canaani J., Itkin T., and Gur-Cohen S., Leukemia, 2013, 27 (10), 2006–15.

Zubkova I., Mostowski H., and Zaitseva M., J. Immunol., 2005, 175 (4), 2321–30.

Konto-Ghiorghi Y. J Pediatrics Child Care, 2013, 1(1), 5.

Narla A., Dutt S., and McAuley JR., Blood, 2011, 118(8), 2296-2304.

Putra WE., Soewondo A., and Rifa'i M., J. Biotropika, 2015, 3(1), 42-45.

Hodrea J., The glucocorticoid deksametasone programs human dendritic cells for enhanced phagocytosis of apoptotic neutrophils and inflammatory response, Doctoral School of Molecular Cell and Immune Biology, University of Debrecen, Hungary, 2011.

Graversen JH., Svendsen P., Dagnæs-Hansen F., Dal J., Anton G., Etzerodt A., Petersen MD., Christensen PA., Møller HJ., and Moestrup SK., Mol. Ther., 2012, 20 (8).

Drewniak A., Van Raam BJ., Geissler J., Tool ATJ., Mook ORF., Van Den BTK., Baas F., and Kuijpers TW., Blood, 2009, 113 (23), 5979-98.

Stroncek DF., Yau YY., Oblitas J., and Leitman SF., Transfusion, 2001, 41(8), 1037-44.

Lee OK., Kuo TK., and Chen WM., Blood, 2004, 103, 1669-75.

Murphy K., Janeway's immuno-biology, 8th ed, 2012, Garland Science, Taylor & Francis Group, LLC, New York.

Rifa’i M., Sri W., Nashi W., The International Medical Journal Malaysia, 2014, 13(1), 35-40.

Rifa'i M., The Open Auto-immunity Journal, 2013, 5, 1-5.

Rifa'i M., J. Trop. Life. Science, 2014, 4(1), 8-13.

Lee Y-H. and Rifa’i M., J. Trop. Life Science, 2011, 1(2).

Gruver-Yates AL. and Cidlowski J., Cells, 2013, 2(2), 202–23. [36] Herr I., Gassler N., Friess H., and Buchler MW., Apoptosis, 2007, 12, 271-291.


Refbacks

  • There are currently no refbacks.